Is there still place for high-dose therapy in the elderly myeloma patients?

被引：0
作者：
Palumbo, A.
Bringhen, S.
Gay, F.
Magarotto, V.
Corso, A.
Offidani, M.
Musto, P.
Boccadoro, M.
机构：
[1] Univ Turin, Azienda Osp S Giovanni Battista, Div Ematol, Turin, Italy
[2] Univ Pavia, IRCCS, Policlin San Matteo, Div Ematol, I-27100 Pavia, Italy
[3] Univ Ancona, Osped Riuniti Bergamo, Clin Ematol Osped Univ, Politec Marche, Ancona, Italy
[4] UOC, CROB, Rionero, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：49 / 50
页数：2
相关论文
共 10 条
  • [1] Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321
    Barlogie, B
    Kyle, RA
    Anderson, KC
    Greipp, PR
    Lazarus, HM
    Hurd, DD
    McCoy, J
    Dakhil, SR
    Lanier, KS
    Chapman, RA
    Cromer, JN
    Salmon, SE
    Durie, B
    Crowley, JC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 929 - 936
  • [2] Facon T, 2006, J CLIN ONCOL, V24, p1S
  • [3] Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma:: results of a multicenter phase 1/2 study
    Mateos, Maria-Victoria
    Hernandez, Jose-M.
    Hernandez, Miguel-T
    Gutierrez, Norma-C.
    Palomera, Luis
    Fuertes, Marta
    Diaz-Mediavilla, Joaquin
    Lahuerta, Juan-J.
    de la Rubia, Javier
    Terol, Maria-Jose
    Sureda, Ana
    Bargay, Joan
    Ribas, Paz
    de Arriba, Felipe
    Alegre, Adrian
    Oriol, Albert
    Carrera, Dolores
    Garcia-Larana, Jos
    Garcia-Sanz, Ramon
    Blade, Joan
    Prosper, Felipe
    Mateo, Gemma
    Esseltine, Dixie-Lee
    de Velde, Helgi van
    San Miguel, Jesus-F.
    [J]. BLOOD, 2006, 108 (07) : 2165 - 2172
  • [4] Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial
    Palumbo, A
    Bringhen, S
    Petrucci, MT
    Musto, P
    Rossini, F
    Nunzi, M
    Lauta, VM
    Bergonzi, C
    Barbui, A
    Caravita, T
    Capaldi, A
    Pregno, P
    Guglielmelli, T
    Grasso, M
    Callea, V
    Bertola, A
    Cavallo, F
    Falco, P
    Rus, C
    Massaia, M
    Mandelli, F
    Carella, AM
    Pogliani, E
    Liberati, AM
    Dammacco, F
    Ciccone, G
    Boccadoro, M
    [J]. BLOOD, 2004, 104 (10) : 3052 - 3057
  • [5] Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
    Palumbo, A
    Bringhen, S
    Coravito, T
    Merla, E
    Capporella, V
    Callea, V
    Cangialosi, C
    Grasso, M
    Rossini, F
    Galli, M
    Catalano, L
    Zamagni, E
    Petrucci, MT
    De Stefano, V
    Ceccarelli, M
    Ambrosini, MT
    Avonto, I
    Falco, P
    Ciccone, G
    Liberati, AM
    Musto, P
    Boccadoro, M
    [J]. LANCET, 2006, 367 (9513) : 825 - 831
  • [6] PALUMBO A, 2006, BLOOD, V108, pA800
  • [7] PALUMBO A, 2006, BLOOD
  • [8] A prospective, randomized, phase III study of melphalan 200 mg/m2 (MEL200) versus melphalan 100 mg/m2 (MEL100) in newly diagnosed myeloma patients.
    Palumbo, Antonio
    Bringhen, Sara
    Petrucci, Maria Teresa
    Falcone, Antonietta
    Liberati, Anna Marina
    Grasso, Mariella
    Pisani, Francesco
    Caravita, Tommaso
    Pregno, Patrizia
    Nozza, Andrea
    Omede, Paola
    Falco, Patrizia
    Musto, Pellegrino
    Foa, Robin
    Boccadoro, Mario
    [J]. BLOOD, 2006, 108 (11) : 21A - 21A
  • [9] Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma
    Palumbo, Antonio
    Avonto, Ilaria
    Bruno, Benedetto
    Falcone, Antonietta
    Scalzulli, Polito Rosario
    Ambrosini, Maria Teresa
    Bringhen, Sara
    Gay, Francesca
    Rus, Cecilia
    Cavallo, Federica
    Falco, Patrizia
    Massaia, Massimo
    Musto, Pellegrino
    Boccadoro, Mario
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (06) : 475 - 477
  • [10] RIES LAG, 2001, SEER CANC STAT REV
1